Augmin prevents merotelic attachments by promoting proper arrangement of bridging and kinetochore fibers

Abstract

The human mitotic spindle is made of microtubules nucleated at centrosomes, at kinetochores, and from pre-existing microtubules by the augmin complex. However, it is unknown how the augmin-mediated nucleation affects distinct microtubule classes and thereby mitotic fidelity. Here we use superresolution microscopy to analyze the previously indistinguishable microtubule arrangements within the crowded metaphase plate area and demonstrate that augmin is vital for the formation of uniformly arranged parallel units consisting of sister kinetochore fibers connected by a bridging fiber. This ordered geometry helps both prevent and resolve merotelic attachments. Whereas augmin-nucleated bridging fibers prevent merotelic attachments by creating a nearly parallel and highly bundled microtubule arrangement unfavorable for creating additional attachments, augmin-nucleated k-fibers produce robust force required to resolve errors during anaphase. STED microscopy revealed that bridging fibers were impaired twice as much as k-fibers following augmin depletion. The complete absence of bridging fibers from a significant portion of kinetochore pairs, especially in the inner part of the spindle, resulted in the specific reduction of the interkinetochore distance. Taken together, we propose a model where augmin promotes mitotic fidelity by generating assemblies consisting of bridging and kinetochore fibers that align sister kinetochores to face opposite poles, thereby preventing erroneous attachments.

Data availability

All source codes and source data have been deposited to the Dryad repository (https://doi.org/10.5061/dryad.fn2z34tz7).

The following data sets were generated

Article and author information

Author details

  1. Valentina Štimac

    Ruđer Bošković Institute, Zagreb, Croatia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0398-5493
  2. Isabella Koprivec

    Ruđer Bošković Institute, Zagreb, Croatia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6486-8261
  3. Martina Manenica

    Ruđer Bošković Institute, Zagreb, Croatia
    Competing interests
    The authors declare that no competing interests exist.
  4. Juraj Simunić

    Ruđer Bošković Institute, Zagreb, Croatia
    Competing interests
    The authors declare that no competing interests exist.
  5. Iva M Tolić

    Ruđer Bošković Institute, Zagreb, Croatia
    For correspondence
    tolic@irb.hr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1305-7922

Funding

European Research Council (ERC Consolidator Grant 647077)

  • Iva M Tolić

Croatian Science Foundation Cooperation Programme (HRZZ project PZS-2019-02-7653)

  • Iva M Tolić

European Regional Development Fund (QuantiXLie Centre of Excellence (KK.01.1.1.01.0004))

  • Iva M Tolić

European Research Council (ERC Synergy Grant 855158)

  • Iva M Tolić

European Regional Development Fund (IPSted (KK.01.1.1.04.0057))

  • Iva M Tolić

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Thomas Surrey, Centre for Genomic Regulation (CRG), Spain

Version history

  1. Preprint posted: September 10, 2020 (view preprint)
  2. Received: September 7, 2022
  3. Accepted: September 26, 2022
  4. Accepted Manuscript published: October 21, 2022 (version 1)
  5. Version of Record published: November 7, 2022 (version 2)

Copyright

© 2022, Štimac et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,797
    views
  • 254
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Valentina Štimac
  2. Isabella Koprivec
  3. Martina Manenica
  4. Juraj Simunić
  5. Iva M Tolić
(2022)
Augmin prevents merotelic attachments by promoting proper arrangement of bridging and kinetochore fibers
eLife 11:e83287.
https://doi.org/10.7554/eLife.83287

Share this article

https://doi.org/10.7554/eLife.83287

Further reading

    1. Cancer Biology
    2. Cell Biology
    Ian Lorimer
    Insight

    Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.

    1. Cancer Biology
    Xia Shen, Xiang Peng ... Chen-Ying Liu
    Research Article

    The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes SAMD4A, AJUBA, and WTIP and transcriptional suppression of the tumor suppressor gene PNRC1 are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (DDX6, DCP1A, and LSM14A), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP5SA in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of SAMD4A, AJUBA, WTIP, PNRC1, and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.